Abstract
Recently a number of glucose dehydrogenase-based point of care (POCT) systems for glucose monitoring were successfully introduced on the market. Icodextrin, a glucose polymer is widely used as an osmotic agent in continuous ambulatory peritoneal dialysis (CAPD). Its metabolites are substrates for glucose dehydrogenase, inducing an analytical error which is gaining importance in the determination of glucose in a hospital environment. Since icodextrin is hydrolysed by amylase in the extracellular fluids, the analytical error in vivo is aggravated by the presence of the smaller oligosaccharides which originate from amylase activity. Clinicians should be warned about the spurious high glucose results which might occur in icodextrin-treated patients. In particular in conditions associated with increased amylase activities, analytical errors are to be expected in icodextrin-treated patients. Alternative glucose determination methods should be recommended in the latter group of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
